| |
|
2024 |
|
2023 |
| |
|
£ |
£ |
|
£ |
£ |
| Fixed assets |
|
|
483 |
|
|
644 |
| Current assets |
|
10,885 |
|
|
22,836 |
|
| Creditors: amount falling due within one year |
|
(6,233) |
|
|
(1,615) |
|
|
Net current assets
|
|
|
4,652
|
|
|
21,221
|
|
Total assets less current liabilities
|
|
|
5,135 |
|
|
21,865 |
|
Net assets
|
|
|
5,135 |
|
|
21,865 |
| |
|
|
|
|
|
|
|
Capital and reserves
|
|
|
5,135 |
|
|
21,865 |
| |
NOTES TO THE ACCOUNTS
General Information
Rasul Eyecare Limited is a private company, limited by shares, registered in England and Wales, registration number 07053313, registration address 217 Albany Road, Roath, Cardiff, CF24 3NW.
| 1. |
Accounting policies
Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 105 The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
|
| 2. |
Average number of employees
Average number of employees during the year was 1 (2023 : 1).
|
| 3. |
Presentational currency
The financial statements are presented in Sterling, which is the presentational currency of the company
|
For the year ended 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's Responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and FRS 105, the Financial Reporting Standard applicable to the micro-entities regime. The accounts have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 18 July 2025 and were signed by: -------------------------------- Hassan Rasul Director |
1
|